Sara A. Hurvitz, MD | Authors

NBV-8S4-11

550 1ST AVE

Articles

Relapsed/Refractory HER2+ Metastatic Breast Cancer

February 15, 2021

Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.

Cardiotoxicity of Targeted Agents in Oncology: A Medical Oncology Perspective

June 15, 2014

Without question, targeted therapies have revolutionized the treatment of cancer across histologies.

Novel Agents in Early Trials for Breast Cancer

July 11, 2012

CancerNetwork speaks with Dr. Sara Hurvitz, director of the breast cancer program at the University of California in Los Angeles. Dr. Hurvitz is actively involved in translational phase I/II breast cancer clinical trials as well as in research to better define distinct types of breast tumors to better design novel targeted therapies.